scispace - formally typeset
Y

Yoichiro Hirata

Researcher at University of Tokyo

Publications -  82
Citations -  2356

Yoichiro Hirata is an academic researcher from University of Tokyo. The author has contributed to research in topics: Inflammation & Adipose tissue. The author has an hindex of 25, co-authored 76 publications receiving 1980 citations. Previous affiliations of Yoichiro Hirata include University of Tokushima.

Papers
More filters
Journal ArticleDOI

Coronary Atherosclerosis Is Associated With Macrophage Polarization in Epicardial Adipose Tissue

TL;DR: The ratio of M1/M2 macrophages in epicardial adipose tissue of CAD patients is changed compared with that in non-CAD patients, and human coronary atherosclerosis is associated with macrophage polarization in epicardsial adiposes tissue.
Journal ArticleDOI

Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance

TL;DR: It is shown that obesity-related adipocyte degeneration causes release of cell-free DNA (cfDNA), which promotes macrophage accumulation in adipose tissue via Toll-like receptor 9 (TLR9), originally known as a sensor of exogenous DNA fragments, which may provide a novel mechanism for the development of sterile inflammation in adipOSE tissue and a potential therapeutic target for insulin resistance.
Journal ArticleDOI

Enhanced inflammation in epicardial fat in patients with coronary artery disease.

TL;DR: It is suggested that inflammatory cell infiltration is enhanced in epicardial adipose tissue, but not in subcutaneous fat, in patients with coronary artery disease.
Journal ArticleDOI

Epicardial Adipose Tissue Volume and Adipocytokine Imbalance Are Strongly Linked to Human Coronary Atherosclerosis

TL;DR: EATV and macrophage and cytokine/adipocytokine signals in EAT strongly correlated with CAD and suggest that EATv and adipocytoksine imbalance are strongly linked to human coronary atherosclerosis.
Journal ArticleDOI

Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice

TL;DR: The hypothesis that rivaroxaban (Riv), a direct FXa inhibitor, inhibits atherogenesis by reducing macrophage activation is assessed, indicating that Riv may be particularly beneficial for the management of atherosclerotic diseases, in addition to its antithrombotic activity.